Article
17 February 2026 - by Matt Berman, Rachel Crum, Rhea D'Silva, Corinne Owens, Jon Yalcin
How can healthcare stakeholders use Six Sigma to transform the Medicare Prescription Payment Plan into a widely adopted and trusted benefit?
Article
03 December 2025 - by Matt Berman, Chris Page, Chad Barker, Corinne Owens
We discuss three critical shifts for life sciences companies to consider in the wake of the FDA’s new structure for approval timelines for selected products.
Article
18 November 2024 - by Matt Berman, Adam Feller, Chad Barker, Jacob Hahn
We explore the Medicare Prescription Payment Plan's benefits and challenges for beneficiaries, emphasizing the need for clear communication and education to enhance understanding and decision-making.
Article
04 September 2024 - by Chad Barker, Chris Page, Matt Berman
In the wake of the FTC’s recent transparency report on pharmacy benefit managers, we look at how reform might impact drug channel stakeholders.
Article
30 September 2022 - by AJ Ally, Matt Berman, Michelle (Klein) Robb, Kevin Pierce
Drug manufacturers should take the time now to understand how the Inflation Reduction Act will affect Medicare and carefully plan.
Article
13 July 2022 - by Matt Berman, Kevin Pierce
We examine various Congressional proposals that would affect insulin, including potential impacts on stakeholders and downstream health equity implications.
Article
16 April 2022 - by AJ Ally, Matt Berman
We discuss three primary targets to reduce prescription drug costs in the U.S., with potentially substantial changes in pricing for Medicare Parts B and D.
Article
22 July 2019 - by Matt Berman, Scott Lain
This report provides data on the burden of diabetes on various subsets of the U.S. population.
Article
30 May 2019 - by Matt Berman, Scott Lain, Luke Metz
This report identifies potential approaches that plan administrators could take in an effort to reduce out-of-pocket costs for insulin-taking members.
Article
27 March 2017 - by Matt Berman, Elizabeth Anne Jackson
This analysis identifies tactics plan administrators could adopt that would reduce out-of-pocket costs for brand-name drugs.
